Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery (Q39006252)

8 September 2017

Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery (English)

1 reference

8 September 2017

Juhong Jiang

1

1 reference

8 September 2017

Yuanzhi Lu

2

1 reference

8 September 2017

Zhi Li

3

1 reference

8 September 2017

Liping Li

4

1 reference

8 September 2017

Daoli Niu

5

1 reference

8 September 2017

Wenwei Xu

6

1 reference

8 September 2017

Jing Liu

7

1 reference

8 September 2017

Lin Fu

8

1 reference

8 September 2017

Ziqing Zhou

9

1 reference

8 September 2017

Yingying Gu

10

1 reference

8 September 2017

Fen Xia

11

1 reference

8 September 2017

23 January 2017

1 reference

Investigational New Drugs

8 September 2017

1 reference

8 September 2017

35

1 reference

8 September 2017

3

1 reference

8 September 2017

251-259

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-016-0424-x

8 September 2017

0 references

cites work

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Structure, function and regulation of the hsp90 machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Heat shock protein 90 as a drug target: some like it hot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Both the charged linker region and ATPase domain of Hsp90 are essential for Rad51-dependent DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Role of PARP inhibitors in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Inhibition of hsp90 compromises the DNA damage response to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

Ganetespib and HSP90: translating preclinical hypotheses into clinical promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0424-X

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28111726

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-016-0424-X

1 reference

8 September 2017

1 reference